Related Experiment Video
Updated: Jun 20, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Erkitinib, a novel EGFR tyrosine kinase inhibitor screened using a ProteoChip system from a phytochemical library
Eung-Yoon Kim1, Young-Jin Choi, Chan-Won Park
1Biochip Research Center, Hoseo University, Asan, Republic of Korea.
Abstract:
Receptor tyrosine kinases (PTKs) play key roles in the pathogenesis of numerous human diseases, including cancer. Therefore PTK inhibitors are currently under intensive investigation as potential drug candidates. Herein, we report on a ProteoChip-based screening of an epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor, Erkitinibs, from phytochemical libraries. PLC-gamma-1 was used as a substrate immobilized on a ProteoChip and incubated with an EGFR kinase to phosphorylate tyrosine residues of the substrate, followed by a fluorescence detection of the substrate recognized by a phospho-specific monoclonal antibody. Erkitinibs inhibited HeLa cell proliferation in a dose-dependent manner. In conclusion, these data suggest that Erkitinibs can be a specific inhibitor of an EGFR kinase and can be further developed as a potent anti-tumor agent.
Insights
Erkitinibs, a phytochemical compound, effectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase (TK) activity. This discovery suggests Erkitinibs
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Receptor tyrosine kinases (PTKs) are implicated in various human diseases, notably cancer, making them targets for drug development.
- Developing novel inhibitors for PTKs is crucial for advancing cancer therapeutics.
Purpose of the Study:
- To screen phytochemical libraries for inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) using a ProteoChip-based assay.
- To evaluate the anti-proliferative effects of identified inhibitors on cancer cells.
Main Methods:
- A ProteoChip was utilized to immobilize PLC-gamma-1 as a substrate for EGFR kinase.
- Phosphorylation of tyrosine residues on the substrate was detected using a phospho-specific monoclonal antibody and fluorescence.
- HeLa cells were treated with potential inhibitors to assess proliferation rates.
Main Results:
- Erkitinibs, a phytochemical compound, was identified as an inhibitor of EGFR kinase.
- Erkitinibs demonstrated dose-dependent inhibition of HeLa cell proliferation.
Conclusions:
- Erkitinibs exhibits specific inhibitory activity against EGFR kinase.
- Erkitinibs shows potential as a novel anti-tumor agent for further development.
